Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

P2RX7 activator HEI-3090 shows promise for treating NSCLC

March 1, 2021

Targeting the LIGHT/LTbR pathway may be a strategy to eliminate leukemia stem cells

March 1, 2021

First patient dosed in phase I/II study of KB-0742

Feb. 26, 2021

Italian researchers present new PTPN11 inhibitors

Feb. 26, 2021

Well Marker Bio presents new MST1R inhibitors

Feb. 26, 2021

ESSA Pharma and Astellas collaborate to investigate EPI-7386 plus enzalutamide in mCRPC

Feb. 26, 2021

Targeting of neoplastic progenitors as new therapeutic strategy in AML

Feb. 26, 2021

Bacterial protease takes on "undruggable" oncoprotein

Feb. 25, 2021

Salarius initiates expansion stage for phase I/II study of seclidemstat in Ewing sarcoma

Feb. 25, 2021

New PTPN11 inhibitors presented by Etern Biopharma

Feb. 25, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 9, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Korsana boosts Alzheimer’s work with reverse merger, $380M financing
BioWorld Science
Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...